I Want To...
Find a Doctor
Find a doctor at The Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center or Johns Hopkins Community Physicians.
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
Johns Hopkins Medicine
Media Relations and Public Affairs
Media Contact: Audrey Huang
December 10, 2007
SILENCING SMALL BUT MIGHTY CANCER INHIBITORS
Researchers from Johns Hopkins and the University of Pennsylvania have uncovered another reason why one of the most commonly activated proteins in cancer is in fact so dangerous. As reported in Nature Genetics this week, the Myc protein can stop the production of at least 13 microRNAs, small pieces of nucleic acid that help control which genes are turned on and off.
What’s more, in several instances, re-introducing repressed miRNAs into Myc-containing cancer cells suppressed tumor growth in mice, raising the possibility that a sort-of gene therapy approach could be effective therapy for treating certain cancers.
A research team led by Joshua Mendell, M.D., Ph.D., assistant professor at the McKusick-Nathans Institute of Genetic Medicine, previously found that Myc could turn on one particular group of growth-promoting miRNAs called the miR-17-92 cluster in lymphoma cells. His team, along with Andrei Thomas-Tikhonenko’s lab at the University of Pennsylvania, now took a broader approach and analyzed more than 300 miRNAs in both human and mouse lymphoma cells.
In those cells that had high amounts of Myc protein, the researchers found significant changes in the quantities of at least 13 miRNAs. “The surprising aspect, considering our miR-17-92 results,” says Tsung-Cheng Chang, lead author on the study, “is that lots of Myc turns everything off, not on.”
When they looked closer at the DNA of the lymphoma cells, the team also found that Myc was directly attaching to the DNA at the miRNA genes. “This was further evidence that the decrease in miRNA levels was directly due to the action of Myc,” says Chang.
“This study expands our understanding of how Myc acts as such a potent cancer-promoting protein,” says Mendell. “We already knew that it can directly regulate thousands of genes. Through its repertoire of miRNAs, Myc likely influences the expression of thousands of additional genes. Activation of Myc therefore profoundly changes the program of genes that are expressed in cancer cells.”
“Still, we needed to determine whether any of these Myc-regulated microRNAs played a direct role in cancer,” adds Thomas-Tikhonenko. His team then individually reintroduced several of the repressed miRNAs into mouse lymphomas that also had high levels of Myc and measured the effect on lymphoma progression in animals. They found that more than five of the miRNAs could stop cancer growth. “While this result was not entirely surprising, we had no idea that cancer suppression by microRNAs could be so powerful,” admits Thomas-Tikhonenko. Mendell also notes that RNA-based therapies have had some success in animal models, and researchers might potentially find a wide range of miRNAs that can stop cancers in their tracks.
The research was funded by the National Institutes of Health.
Authors on the paper are Duonan Yu and Andrei Thomas-Tikhonenko of the University of Pennsylvania and Tsung-Cheng Chang, Yun-Sil Lee, Erik Wentzel, Dan Arking, Kristin West, Chi Dang and Joshua Mendell of Hopkins.
On the Web: